The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase III randomized study of nivolumab plus ipilimumab versus nivolumab for previously treated patients with stage IV squamous cell lung cancer and no matching biomarker (Lung-MAP Sub-Study S1400I, NCT02785952).
 
Lyudmila Bazhenova
Stock and Other Ownership Interests - Epic Sciences
Consulting or Advisory Role - Abbvie; AstraZeneca; Boston Biomedical; Genentech/Roche; Lilly; Loxo; Pfizer; Takeda
Research Funding - BeyondSpring Pharmaceuticals
 
Mary Weber Redman
Consulting or Advisory Role - Ignyta; Ignyta
 
Scott N. Gettinger
Consulting or Advisory Role - Bristol-Myers Squibb; NEKTAR
Research Funding - ARIAD/Takeda (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst)
 
Fred R. Hirsch
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Genentech; HTG Molecular Diagnostics; Lilly; Merck; Pfizer; Roche; Ventana Medical Systems
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Lilly/ImClone (Inst)
Patents, Royalties, Other Intellectual Property - EGFR FISH and IHC for prediction of outcome in patients treated with EGFR inhibitors (Inst)
 
Philip C. Mack
Honoraria - Guardant Health
Consulting or Advisory Role - AstraZeneca; Guardant Health; Pfizer
Research Funding - Boehringer Ingelheim
 
Lawrence Howard Schwartz
Consulting or Advisory Role - Novartis; Roche
Research Funding - Daiichi Sankyo (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Millenium Pharamceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Varian Medical Systems
 
David R. Gandara
No Relationships to Disclose
 
Jeffrey D. Bradley
Honoraria - AstraZeneca/MedImmune
Consulting or Advisory Role - AstraZeneca/MedImmune
Travel, Accommodations, Expenses - Mevion Medical Systems
 
Tom Stinchcombe
Consulting or Advisory Role - AstraZeneca; G1 Therapeutics; G1 Therapeutics; Genentech/Roche; Novartis; Regeneron; Takeda
Research Funding - AstraZeneca (Inst); Blueprint Medicines (Inst); Genentech/Roche (Inst); Merck (Inst); Takeda (Inst)
 
Natasha B. Leighl
Research Funding - Novartis (Inst); Roche Canada (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Merck Sharp & Dohme; Nektar; Pfizer; Roche; Roche/Genentech
 
Suresh S. Ramalingam
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; Lilly/ImClone; Loxo; Merck; Nektar; Takeda; Tesaro
Research Funding - Abbvie (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Merck (Inst); Merck (Inst); Pfizer (Inst); Takeda (Inst); Vertex (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Susan S Tavernier
No Relationships to Disclose
 
Katherine Minichiello
No Relationships to Disclose
 
Karen Kelly
Honoraria - Merck
Consulting or Advisory Role - Abbvie; AstraZeneca; EMD Serono; Genentech/Roche; Janssen; Lilly; Merck; Pfizer; Regeneron
Research Funding - Abbvie (Inst); Celgene (Inst); EMD Serono (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Lilly (Inst); Lycera (Inst); Regeneron (Inst); Transgene (Inst)
Patents, Royalties, Other Intellectual Property - Author Royalties for UpToDate, an evidence based, peer reviewed information resource, available via the web, desktop, and PDA.
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; EMD Serono; Genentech/Roche; Lilly; Merck; Regeneron
 
Vassiliki Papadimitrakopoulou
Consulting or Advisory Role - Abbvie; Araxes Pharma; ARIAD; Arrys Therapeutics; AstraZeneca; Biothera; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Genentech; Genentech; Gritstone Bio; Janssen; Lilly; Loxo; Merck; Nektar; Novartis; Pfizer; Takeda; Tesaro; TRM Oncology
Research Funding - ACEA Biosciences (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Checkmate Pharmaceuticals (Inst); Checkmate Pharmaceuticals (Inst); Checkmate Pharmaceuticals (Inst); Clovis Oncology (Inst); Guardant Health (Inst); Incyte (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Roche; Roche
Other Relationship - Roche
 
Roy S. Herbst
Leadership - Junshi Pharmaceuticals
Consulting or Advisory Role - Abbvie; AstraZeneca; Biodesix; Bristol-Myers Squibb; EMD Serono; Genentech/Roche; Heat Biologics; Infinity Pharmaceuticals; Junshi Pharmaceuticals; Lilly; Loxo; Merck; Nektar; Neon Therapeutics; NextCure; Novartis; Pfizer; Sanofi; Seagen; Shire; Spectrum Pharmaceuticals; Symphogen; TESARO
Research Funding - AstraZeneca; Lilly; Merck